Impact of perioperative red blood cell transfusion on the prognosis of patients with epithelial ovarian cancer Authors: Yawen Zheng, Wenxia Zhang, Yafei Chen, Xingsheng Yang, Ruiying Dong Published: 2023 ABSTRACT BackgroundSurgery for advanced ovarian cancer tends to be extensive. We performed an analysis to determine whether perioperative red blood cell transfusion (PRBCT) is associated with a poor prognosis in women with epithelial ovarian cancer (EOC).MethodsOur retrospective analysis included 314 women. The Mann-Whitney rank-sum test and chi-square test were used to analyze the clinical characteristics of the PRBCT and non-PRBCT groups, and Cox proportional hazard models were used for the multivariate analysis.ResultsPRBCT was associated with higher relapse and mortality rates in 121 (38.54 %) patients. After multivariate analysis, transfused patients were 1.59 times at risk of death (hazard ratio [HR] = 1.59; 95%CI, 1.12–2.25) and 1.63 times at risk of recurrence (HR = 1.63; 95%CI, 1.22–2.18) than non-transfused patients.ConclusionsPRBCT could prolong hospital stay, and increased hospital costs were significantly associated with increased cancer recurrence and overall mortality in patients with EOC. Introduction Ovarian cancer is the eighth leading cause of death from cancer among women and ranks second to cervical cancer among gynecologic tumor-related deaths worldwide [1]. Epithelial ovarian cancer (EOC) is the most common ovarian cancer. Most EOCs are diagnosed at an advanced stage because effective screening tests are lacking and clinical symptoms are non-specific. More than 70 % of all patients have stage III or IV diseases at diagnosis with a five-year survival rate of less than 20 % [2]. Primary debulking surgery (PDS) and platinum/taxane-based chemotherapy are the standard treatments for advanced EOC. Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is considered an alternative treatment for patients with serious complications or an unresectable high tumor burden [3]. Optimal cytoreduction is defined as residual disease less than 1 cm in maximum diameter or thickness; however, maximal effort should be made to remove all gross disease since resection to R0 offers superior survival outcomes [4,5]. Patients with ovarian cancer experience a high rate of anemia throughout their treatment course, with rates in different studies that range from 19 to 95 % [6]. The reported perioperative blood transfusion rate for PDS patients ranges from 19 % to 56 % [7,8]. As the most effective treatment for hypovolemic shock and anemia, perioperative red blood cell transfusion (PRBCT) can enhance patient's tolerance and accelerate recovery, guaranteeing the safety of the operation. However, some studies have indicated that patients who undergo PBRCT usually have prolonged hospital stays and a poor prognosis [[9], [10], [11]]. The mechanism may concern the immunosuppression caused by RBC transfusion, a process known as ‘transfusion-related immunomodulation (TRIM)’. TRIM includes a series of complicated immunological responses that can reduce immune surveillance and cause an immunosuppressive state, contributing to tumor development and recurrence [12]. However, the effect of PRBCT on EOC patients is still controversial [9,13,14]. A recent study that included 612 patients with advanced ovarian cancer showed that transfusion was associated with increased perioperative morbidity without improved quality of life but did not negatively impact progression-free survival (PFS) or overall survival (OS) [15]. However, in contrast, a retrospective study including 1037 patients found that PRBCT was significantly associated with higher postoperative complication rates, increased cancer recurrence and overall mortality [14]. Thus, considering the potential negative impacts of excess transfusions, some studies in recent years have shown that establishing a blood transfusion policy and adopting reasonable transfusion thresholds might improve overall and disease-free survival, and decrease the recurrence rate in EOC [16,17]. Therefore, this retrospective study was designed to analyze the impact of PRBCT on postoperative recovery and long-term survival outcomes and promote a rational blood transfusion policy for patients with EOC. Methods Data source This retrospective study enrolled 337 patients aged 18–70 who were diagnosed with EOC from January 2014 to December 2016 at the Gynecologic Oncology Department of Qilu Hospital of Shandong University. The patients underwent PDS or NACT-IDS and achieved complete remission (CR) or partial remission (PR). The exclusion criteria were incomplete medical records, unknown primary tumor sites, other malignancies, and blood or immune system diseases. This study was conducted according to the Declaration of Helsinki and was approved by the Institutional Ethics committee of Qilu Hospital (IRB No. KYLL-2022 (ZM)-484). Informed consent was obtained from all patients. The data were extracted from the Qilu Hospital Clinical Record Search System database. Each patient's medical information, including demographic information, diagnosis, medical history, American Society of Anesthesiologists (ASA) grade, surgical details (operative time, residual tumor, amount of ascites, and estimated blood loss volume), pathological details (histologic type, tumor size, tumor differentiation, and FIGO stage), preoperative hemoglobin and CA-125 levels, total perioperative infusion volume of allogeneic red blood cells (RBCs), number of RBC transfusions, and postoperative outcomes, was reviewed and recorded. Patients were followed up every three months for the first year and then every six months. Follow-ups included subsequent treatment, recurrence, and survival. The follow-up deadline was June 2020. OS was defined as survival from the date of treatment to the date of death or the last follow-up date. PFS was defined as the time from treatment initiation until disease progression according to the RECIST v1.1 and GCIG criteria [18]. Satisfactory debulking surgery was defined as the absence of a residual tumor (R0) or a residual tumor < 1 cm in size (R1). If the residual tumor is more than 1 cm, it's unsatisfactory debulking surgery. PRBCT was defined as the transfusion of at least one unit of allogeneic RBCs during preoperative or postoperative hospital admission. Standard chemotherapy was defined as six courses of platinum/taxane-based chemotherapy for stage I high-grade serous ovarian cancer patients and stage II-IV EOC patients, and three to six courses for other types of stage I according to the NCCN guidelines [4]. Statistical analysis Patients who underwent PRBCT were classified into the PRBCT group, and those who did not undergo PRBCT were classified into the non-PRBCT group. The Mann-Whitney rank-sum and chi-square tests were used to analyze the clinical characteristics between the two groups. Overall survival was estimated by the Kaplan–Meier method, and comparisons of statistical significance were performed with the stratified log-rank test within each group. Multivariate analysis was performed using multivariable. Cox proportional hazards models were used to compare the significant factors in the univariate analysis. Data were analyzed using the SPSS software (IBM SPSS 26.0, SPSS Inc). All statistical tests were two-sided, with P values less than 0.05 considered statistically significant. Results Among 337 patients diagnosed with EOC between 2014 and 2016, 23 (6.82 %) were lost to follow-up. Thus, 314 patients with EOC were enrolled in this study, with a median age of 53 years (range:20–69) at diagnosis Fig. 1 shows the epidemiological information of all enrolled patients. The majority of patients were in the advanced stage (stage III/IV) (77.39 %, 243/314, Fig. 1A) and had a high ASA grade (90.76 %, 285/314, Fig. 1F). Most patients had severe carcinoma (78.34 %, 246/314) and were diagnosed with G3 disease (84.71 %, 266/314, Fig. 1E). In addition, a large number of patients underwent PDS (79.30 %, 249/314, Fig. 1D), and approximately 40.76 % (128/314) underwent lymph node dissection. All patients at stage I/II underwent satisfactory debulking surgery while only 68.72 % (167/243) of those at stage III/IV underwent satisfactory debulking surgery (Fig. 1C). Notably, only 81.61 % of patients in stage I and II and 60.91 % of patients in stages III and IV received standard courses of chemotherapy (P < 0.05, Fig. 1B).Fig. 1Epidemiological information of all EOC patients. (A) Shows the proportion of different histologic type in early (stage I/II) and advanced (stage III/IV) EOC. (B) and (C) show the completion of chemotherapy and surgery, according to NCCN guideline, the standard course for stage I high-grade serous ovarian cancer patients and stage II-IV EOC patients is 6; for other type of stage I, the standard course is 3–6. The satisfactory debulking surgery was defined as no residual tumor (R0) and residual tumor < 1 cm (R1). The proportion of treatment, tumor differentiation, ASA grade and RBC transfusion are presented in the pie charts (D), (E), (F) and (G).LGSC: Low grade serous carcinoma; HGSC: High grade serous carcinoma; PDS: Primary debulking surgery; NACT: Neoadjuvant chemotherapy; PRBCT: Perioperative red blood cell transfusion; non-PRBCT: Non-perioperative red blood cell transfusion. G1: Well differentiated; G2: Moderately differentiated; G3: Poorly differentiated. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)Fig. 1 Epidemiological information of all EOC patients. (A) Shows the proportion of different histologic type in early (stage I/II) and advanced (stage III/IV) EOC. (B) and (C) show the completion of chemotherapy and surgery, according to NCCN guideline, the standard course for stage I high-grade serous ovarian cancer patients and stage II-IV EOC patients is 6; for other type of stage I, the standard course is 3–6. The satisfactory debulking surgery was defined as no residual tumor (R0) and residual tumor < 1 cm (R1). The proportion of treatment, tumor differentiation, ASA grade and RBC transfusion are presented in the pie charts (D), (E), (F) and (G). LGSC: Low grade serous carcinoma; HGSC: High grade serous carcinoma; PDS: Primary debulking surgery; NACT: Neoadjuvant chemotherapy; PRBCT: Perioperative red blood cell transfusion; non-PRBCT: Non-perioperative red blood cell transfusion. G1: Well differentiated; G2: Moderately differentiated; G3: Poorly differentiated. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) A total of 121 (38.54 %) patients were classified into the PRBCT group, and 193 patients were classified into the non-PRBCT group (Fig. 1G). The demographic and clinical characteristics of the two groups are summarized in Table 1. Our analysis showed that PRBCT was associated with higher preoperative serum CA-125 levels (Mean ± SD, 1532.20 ± 157521 vs. 829.12 ± 1073.22 U/ml, P < 0.05), higher intraoperative blood loss (Mean ± SD, 853.31 ± 853.13 vs. 306.92 ± 170.61 ml, P < 0.05), a larger amount of ascites (Mean ± SD, 1243.04 ± 1595.14 vs. 604.42 ± 1131.23 ml, P < 0.05), and a lower hemoglobin level at diagnosis (Mean ± SD, 11.51 ± 1.71 vs. 12.42 ± 1.42 g/dL, P = 0.002). Moreover, the patients in the PRBCT group had a longer operative time (Mean ± SD, 171.73 ± 69.44 vs. 144.84 ± 55.93 time, P < 0.05) and were less likely to receive lymph node dissection (32.23 % vs. 46.11 %, P = 0.02). Table 2 describes the patient outcomes in the two groups. Strikingly, the PRBCT group had a lower likelihood of satisfactory debulking surgery than the non-PRBCT group (66.12 % vs. 81.87 %, P = 0.002), with higher relapse (90.08 % vs. 63.73 %) and mortality rates (62.81 % vs. 42.49 %).Table 1Baseline characteristics of patients in study.Table 1Group PRBCTN = 121Group non-PRBCTN = 193p-valueAge at diagnosis, median (SE), y53.86 (10.12)52.39 (9.32)0.205CA-125, mean (SE), U/ml1532.20 (1575.21)829.12 (1073.22)<0.05FIGO stageStage I-II11 (9.09 %)60 (31.08 %)Stage III-IV110 (90.91 %)133 (68.92 %)<0.05Maximum tumor diameter, cm<5 cm37 (30.58 %)69 (35.75 %)≥5 cm84 (69.42 %)124 (64.25 %)0.486LymphadenectomyYes39 (32.23 %)89 (46.11 %)No82 (67.77 %)104 (53.89 %)0.02Residual tumorSatisfactory80 (66.12 %)158 (81.87 %)Unsatisfactory41 (33.88 %)35 (18.13 %)0.002TreatmentPDS98 (80.99 %)151 (78.24 %)NACT23 (19.01 %)42 (21.76 %)>0.05Amount of ascites, mean (SE), ml1243.04 (1595.14)604.42 (1131.23)<0.05Blood loss, mean (SE), ml853.31 (853.13)306.92 (170.61)<0.05Operative time, mean (SE), min171.73 (69.44)144.84 (55.93)<0.05Hospitalization days, mean (SE)17.50 (5.81)16.12 (6.01)0.07Hemoglobin at diagnosis, mean (SE), g/dL11.51 (1.71)12.42 (1.42)0.002Postoperative Hemoglobin*, mean (SE), g/dL11.01 (1.52)10.42 (1.53)0.003Preoperative anaemiaYes44 (36.36 %)28 (14.51 %)No77 (63.64 %)165 (85.49 %)<0.05*: Postoperative Hemoglobin means the hemoglobin of the first day after surgery. p-values are results of Chi-square test. Abbreviations: SE, standard error; PDS: Primary debulking surgery; NACT: Neoadjuvant chemotherapy; PRBCT: Perioperative red blood cell transfusion.Table 2Outcomes of patients in study and distribution of PRBCT cases at the restrictive threshold.Table 2Outcomes of patients in studyDistribution of PRBCT cases at the restrictive thresholdGroup PRBCTN = 121Group non-PRBCTN = 193p-valuePre-transfusion Hgb levelnumberpercentBlood loss, mean (SE), mlRecurrence≤ 7 g/dL1310.74 %860.72 (862.81)Yes109 (90.08 %)123 (63.73 %)No12 (9.92 %)70 (36.27 %)<0.05> 7 g/dL ≤ 8 g/dL1915.71 %843.79 (850.74)DeathYes76 (62.81 %)82 (42.49 %)> 8 g/dL8973.55 %854.24 (849.49)No45 (37.19 %)111 (57.51 %)0.001p-values are results of Chi-square test. Abbreviations: PRBCT: Perioperative red blood cell transfusion; non-PRBCT: Non-perioperative red blood cell transfusion; Hgb: Hemoglobin; SE, standard error. Table 1Baseline characteristics of patients in study.Table 1Group PRBCTN = 121Group non-PRBCTN = 193p-valueAge at diagnosis, median (SE), y53.86 (10.12)52.39 (9.32)0.205CA-125, mean (SE), U/ml1532.20 (1575.21)829.12 (1073.22)<0.05FIGO stageStage I-II11 (9.09 %)60 (31.08 %)Stage III-IV110 (90.91 %)133 (68.92 %)<0.05Maximum tumor diameter, cm<5 cm37 (30.58 %)69 (35.75 %)≥5 cm84 (69.42 %)124 (64.25 %)0.486LymphadenectomyYes39 (32.23 %)89 (46.11 %)No82 (67.77 %)104 (53.89 %)0.02Residual tumorSatisfactory80 (66.12 %)158 (81.87 %)Unsatisfactory41 (33.88 %)35 (18.13 %)0.002TreatmentPDS98 (80.99 %)151 (78.24 %)NACT23 (19.01 %)42 (21.76 %)>0.05Amount of ascites, mean (SE), ml1243.04 (1595.14)604.42 (1131.23)<0.05Blood loss, mean (SE), ml853.31 (853.13)306.92 (170.61)<0.05Operative time, mean (SE), min171.73 (69.44)144.84 (55.93)<0.05Hospitalization days, mean (SE)17.50 (5.81)16.12 (6.01)0.07Hemoglobin at diagnosis, mean (SE), g/dL11.51 (1.71)12.42 (1.42)0.002Postoperative Hemoglobin*, mean (SE), g/dL11.01 (1.52)10.42 (1.53)0.003Preoperative anaemiaYes44 (36.36 %)28 (14.51 %)No77 (63.64 %)165 (85.49 %)<0.05*: Postoperative Hemoglobin means the hemoglobin of the first day after surgery. p-values are results of Chi-square test. Abbreviations: SE, standard error; PDS: Primary debulking surgery; NACT: Neoadjuvant chemotherapy; PRBCT: Perioperative red blood cell transfusion. Baseline characteristics of patients in study. *: Postoperative Hemoglobin means the hemoglobin of the first day after surgery. p-values are results of Chi-square test. Abbreviations: SE, standard error; PDS: Primary debulking surgery; NACT: Neoadjuvant chemotherapy; PRBCT: Perioperative red blood cell transfusion. Table 2Outcomes of patients in study and distribution of PRBCT cases at the restrictive threshold.Table 2Outcomes of patients in studyDistribution of PRBCT cases at the restrictive thresholdGroup PRBCTN = 121Group non-PRBCTN = 193p-valuePre-transfusion Hgb levelnumberpercentBlood loss, mean (SE), mlRecurrence≤ 7 g/dL1310.74 %860.72 (862.81)Yes109 (90.08 %)123 (63.73 %)No12 (9.92 %)70 (36.27 %)<0.05> 7 g/dL ≤ 8 g/dL1915.71 %843.79 (850.74)DeathYes76 (62.81 %)82 (42.49 %)> 8 g/dL8973.55 %854.24 (849.49)No45 (37.19 %)111 (57.51 %)0.001p-values are results of Chi-square test. Abbreviations: PRBCT: Perioperative red blood cell transfusion; non-PRBCT: Non-perioperative red blood cell transfusion; Hgb: Hemoglobin; SE, standard error. Outcomes of patients in study and distribution of PRBCT cases at the restrictive threshold. p-values are results of Chi-square test. Abbreviations: PRBCT: Perioperative red blood cell transfusion; non-PRBCT: Non-perioperative red blood cell transfusion; Hgb: Hemoglobin; SE, standard error. Among the 121 patients who received RBC transfusion, most (99, 81.81 %) received intraoperative transfusion with a mean preoperative hemoglobin of 8.69 g/dL (range: 5.40–11.40), and the mean amount of blood transfused was 4.79 units (range: 2–24) (Supplementary Table 1). Most patients (56.89 %) received four units of PRBCT, approximately 17.25 % received only two units of RBC, and 23.37 % of patients received more than four units of PRBCT (range: 5–24). According to the restrictive threshold in the transfusion guidelines released by the American Association of Blood Banks in 2016 [19], we analyzed our cohort and found that, with no significant increase in blood loss, only 13 patients (10.74 %) who underwent PRBCT met the threshold criteria (Table 2). Univariate analysis of the factors associated with the survival of patients is shown in Table 3. It demonstrated that patients with non-serous carcinoma, advanced stage, unsatisfactory debulking surgery, surgery without lymph node dissection, and non-standard courses of chemotherapy were more likely to experience decreased survival time. In addition, the OS and PFS rates 3 years after surgery were significantly lower in the PRBCT group than in the non-PRBCT group (48.79 % vs. 70.51 % and 15.91 % vs. 42.42 %, respectively; P < 0.05) (Table 3). The Kaplan-Meier curves for 3-years OS (HR:1.79, 95%CI:1.32–2.45, P < 0.05; Fig. 2A) and PFS (HR: 1.83, 95%CI:1.42–2.32, P < 0.05; Fig. 2B) of the two groups were significantly different.Table 3Univariable analysis of factors associated with EOC survival.Table 3CharacteristicOSPFS3-year OSx2p-value3-year PFSx2p-valueAge <5366.72 %2.390.13236.28 %0.090.769 ≥5357.23 %27.61 %Histologic type Serous carcinoma58.81 %7.760.00527.52 %12.080.001 Non-serous carcinoma76.31 %52.13 %ASA Grade I79.32 %2.150.14379.32 %2.150.143 II60.41 %60.41 %Maximum tumor diameter <5 cm51.89 %7.440.00622.11 %6.990.008 ≥5 cm67.34 %37.01 %PRBCT Yes48.79 %16.79<0.0515.91 %33.90<0.05 No70.51 %42.42 %Preoperative anaemia Yes59.21 %1.320.25023.91 %6.350.130 No53.54 %36.22 %FIGO stage Stage I-II85.91 %30.90<0.0569.22 %49.60<0.05 Stage III-IV55.13 %21.73 %Surgical complexity Satisfactory68.54 %19.46<0.0537.02 %18.06<0.05 Unsatisfactory42.12 %17.04 %Treatment PDS67.93 %19.20<0.0538.51 %24.40<0.05 NACT40.00 %7.84 %Lymphadenectomy Yes75.79 %26.30<0.0573.28 %35.70<0.05 No52.71 %19.82 %Tumor differentiation Well differentiated64.57 %1.690.19447.72 %8.240.004 Moderately/poorly differentiated61.68 %29.23 %Courses of chemotherapy Less53.91 %9.780.00226.63 %5.930.150 Standard*67.71 %36.13 %Abbreviations: OS: Overall survival; PFS: Progression free survival; HR: Hazard ratio; 95 % CI: 95 % confidence intervals; ASA: American Society of Anesthesiologists; PRBCT: Perioperative red blood cell transfusion; FIGO: International Federation of Gynecology and Obstetrics; PDS: Primary debulking surgery; NACT: Neoadjuvant chemotherapy. *All EOC patients are recommended to conduct platinum/taxane-based chemotherapy except stage IA/IB for mucinous, low-grade serous, and grade 1 endometrioid ovarian cancer according to NCCN guideline. The recommended course for stage I high-grade serous ovarian cancer patients and stage II-IV EOC patients is 6; for other type of stage I, the recommended course is 3–6.Fig. 2Kaplan-Meier survival curves. Kaplan-Meier survival curves for 3-year OS (A) and PFS(B) in PRBCT group and non-PRBCT group.Fig. 2 Table 3Univariable analysis of factors associated with EOC survival.Table 3CharacteristicOSPFS3-year OSx2p-value3-year PFSx2p-valueAge <5366.72 %2.390.13236.28 %0.090.769 ≥5357.23 %27.61 %Histologic type Serous carcinoma58.81 %7.760.00527.52 %12.080.001 Non-serous carcinoma76.31 %52.13 %ASA Grade I79.32 %2.150.14379.32 %2.150.143 II60.41 %60.41 %Maximum tumor diameter <5 cm51.89 %7.440.00622.11 %6.990.008 ≥5 cm67.34 %37.01 %PRBCT Yes48.79 %16.79<0.0515.91 %33.90<0.05 No70.51 %42.42 %Preoperative anaemia Yes59.21 %1.320.25023.91 %6.350.130 No53.54 %36.22 %FIGO stage Stage I-II85.91 %30.90<0.0569.22 %49.60<0.05 Stage III-IV55.13 %21.73 %Surgical complexity Satisfactory68.54 %19.46<0.0537.02 %18.06<0.05 Unsatisfactory42.12 %17.04 %Treatment PDS67.93 %19.20<0.0538.51 %24.40<0.05 NACT40.00 %7.84 %Lymphadenectomy Yes75.79 %26.30<0.0573.28 %35.70<0.05 No52.71 %19.82 %Tumor differentiation Well differentiated64.57 %1.690.19447.72 %8.240.004 Moderately/poorly differentiated61.68 %29.23 %Courses of chemotherapy Less53.91 %9.780.00226.63 %5.930.150 Standard*67.71 %36.13 %Abbreviations: OS: Overall survival; PFS: Progression free survival; HR: Hazard ratio; 95 % CI: 95 % confidence intervals; ASA: American Society of Anesthesiologists; PRBCT: Perioperative red blood cell transfusion; FIGO: International Federation of Gynecology and Obstetrics; PDS: Primary debulking surgery; NACT: Neoadjuvant chemotherapy. *All EOC patients are recommended to conduct platinum/taxane-based chemotherapy except stage IA/IB for mucinous, low-grade serous, and grade 1 endometrioid ovarian cancer according to NCCN guideline. The recommended course for stage I high-grade serous ovarian cancer patients and stage II-IV EOC patients is 6; for other type of stage I, the recommended course is 3–6. Univariable analysis of factors associated with EOC survival. Abbreviations: OS: Overall survival; PFS: Progression free survival; HR: Hazard ratio; 95 % CI: 95 % confidence intervals; ASA: American Society of Anesthesiologists; PRBCT: Perioperative red blood cell transfusion; FIGO: International Federation of Gynecology and Obstetrics; PDS: Primary debulking surgery; NACT: Neoadjuvant chemotherapy. *All EOC patients are recommended to conduct platinum/taxane-based chemotherapy except stage IA/IB for mucinous, low-grade serous, and grade 1 endometrioid ovarian cancer according to NCCN guideline. The recommended course for stage I high-grade serous ovarian cancer patients and stage II-IV EOC patients is 6; for other type of stage I, the recommended course is 3–6. Kaplan-Meier survival curves. Kaplan-Meier survival curves for 3-year OS (A) and PFS(B) in PRBCT group and non-PRBCT group. A Cox multivariate proportional hazard regression analysis was performed using significant variables following the univariate analysis. Multivariate analysis revealed that PRBCT was significantly associated with OS [HR (95%CI) = 1.59 (1.12, 2.25), P = 0.009] and disease-free survival [HR (95%CI) = 1.63 (1.22, 2.18), P = 0.001] (Table 4). Other variables associated with the prognosis of patients with EOC included advanced stage (stage III/IV), unsatisfactory debulking surgery, and the absence of lymph node dissection (Table 4).Table 4Multivariable analysis of factors associated with EOC survival.Table 4CharacteristicOSPFSHR (95%CI)p-valueHR (95%CI)p-valueAge <531.00 (referent)Referent1.00 (referent)Referent ≥530.87 (0.62–1.22)0.4171.30 (0.83–2.04)0.245Histologic type Serous carcinoma1.00 (referent)Referent1.00 (referent)Referent Non-serous carcinoma1.27 (0.72–2.24)0.4081.30 (0.83–0.04)0.245ASA Grade I1.00 (referent)Referent1.00 (referent)Referent II1.03 (0.55–1.92)0.9340.95 (0.57–1.56)0.825Maximum tumor diameter <5 cm1.00 (referent)Referent1.00 (referent)Referent ≥5 cm0.90 (0.62–1.31)0.0010.93 (0.68–1.28)0.656PRBCT Yes1.59 (1.12–2.25)0.0091.63 (1.22–2.18)0.001 No1.00 (referent)Referent1.00 (referent)ReferentPreoperative anaemia Yes1.04 (0.73–1.47)0.831.14 (0.73–1.38)0.365 No1.00 (referent)Referent1.00 (referent)ReferentFIGO stage Stage I-II1.00 (referent)Referent1.00 (referent)Referent Stage III-IV2.54 (1.33–4.86)0.0052.24 (1.40–3.58)0.001Surgical complexity Satisfactory1.00 (referent)Referent1.00 (referent)Referent Unsatisfactory1.79 (1.20–2.69)0.0041.67 (1.17–2.38)0.005Treatment PDS1.00 (referent)Referent1.00 (referent)Referent NACT1.16 (0.80–1.69)0.4431.00 (0.73–1.38)0.998Lymphadenectomy Yes0.58 (0.40 to 0.86)0.0070.60 (0.44–0.81)0.001 No1.00 (referent)Referent1.00 (referent)ReferentTumor differentiation Well differentiated1.00 (referent)Referent1.00 (referent)Referent Moderately/poorly differentiated0.95 (0.44–1.24)0.2540.97 (0.62–1.54)0.903Courses of chemotherapy Less0.73 (0.53–1.01)0.0610.88 (0.67–1.15)0.335 Standard*1.00 (referent)Referent1.00 (referent)ReferentAbbreviations: OS: Overall survival; PFS: Progression free survival; HR: Hazard ratio; 95 % CI: 95 % confidence intervals; ASA: American Society of Anesthesiologists; PRBCT: Perioperative red blood cell transfusion; FIGO: International Federation of Gynecology and Obstetrics; PDS: Primary debulking surgery; NACT: Neoadjuvant chemotherapy. *All EOC patients are recommended to conduct platinum/taxane-based chemotherapy except stage IA/IB for mucinous, low-grade serous, and grade 1 endometrioid ovarian cancer according to NCCN guideline. The recommended course for stage I high-grade serous ovarian cancer patients and stage II-IV EOC patients is 6; for other type of stage I, the recommended course is 3–6. Table 4Multivariable analysis of factors associated with EOC survival.Table 4CharacteristicOSPFSHR (95%CI)p-valueHR (95%CI)p-valueAge <531.00 (referent)Referent1.00 (referent)Referent ≥530.87 (0.62–1.22)0.4171.30 (0.83–2.04)0.245Histologic type Serous carcinoma1.00 (referent)Referent1.00 (referent)Referent Non-serous carcinoma1.27 (0.72–2.24)0.4081.30 (0.83–0.04)0.245ASA Grade I1.00 (referent)Referent1.00 (referent)Referent II1.03 (0.55–1.92)0.9340.95 (0.57–1.56)0.825Maximum tumor diameter <5 cm1.00 (referent)Referent1.00 (referent)Referent ≥5 cm0.90 (0.62–1.31)0.0010.93 (0.68–1.28)0.656PRBCT Yes1.59 (1.12–2.25)0.0091.63 (1.22–2.18)0.001 No1.00 (referent)Referent1.00 (referent)ReferentPreoperative anaemia Yes1.04 (0.73–1.47)0.831.14 (0.73–1.38)0.365 No1.00 (referent)Referent1.00 (referent)ReferentFIGO stage Stage I-II1.00 (referent)Referent1.00 (referent)Referent Stage III-IV2.54 (1.33–4.86)0.0052.24 (1.40–3.58)0.001Surgical complexity Satisfactory1.00 (referent)Referent1.00 (referent)Referent Unsatisfactory1.79 (1.20–2.69)0.0041.67 (1.17–2.38)0.005Treatment PDS1.00 (referent)Referent1.00 (referent)Referent NACT1.16 (0.80–1.69)0.4431.00 (0.73–1.38)0.998Lymphadenectomy Yes0.58 (0.40 to 0.86)0.0070.60 (0.44–0.81)0.001 No1.00 (referent)Referent1.00 (referent)ReferentTumor differentiation Well differentiated1.00 (referent)Referent1.00 (referent)Referent Moderately/poorly differentiated0.95 (0.44–1.24)0.2540.97 (0.62–1.54)0.903Courses of chemotherapy Less0.73 (0.53–1.01)0.0610.88 (0.67–1.15)0.335 Standard*1.00 (referent)Referent1.00 (referent)ReferentAbbreviations: OS: Overall survival; PFS: Progression free survival; HR: Hazard ratio; 95 % CI: 95 % confidence intervals; ASA: American Society of Anesthesiologists; PRBCT: Perioperative red blood cell transfusion; FIGO: International Federation of Gynecology and Obstetrics; PDS: Primary debulking surgery; NACT: Neoadjuvant chemotherapy. *All EOC patients are recommended to conduct platinum/taxane-based chemotherapy except stage IA/IB for mucinous, low-grade serous, and grade 1 endometrioid ovarian cancer according to NCCN guideline. The recommended course for stage I high-grade serous ovarian cancer patients and stage II-IV EOC patients is 6; for other type of stage I, the recommended course is 3–6. Multivariable analysis of factors associated with EOC survival. Abbreviations: OS: Overall survival; PFS: Progression free survival; HR: Hazard ratio; 95 % CI: 95 % confidence intervals; ASA: American Society of Anesthesiologists; PRBCT: Perioperative red blood cell transfusion; FIGO: International Federation of Gynecology and Obstetrics; PDS: Primary debulking surgery; NACT: Neoadjuvant chemotherapy. *All EOC patients are recommended to conduct platinum/taxane-based chemotherapy except stage IA/IB for mucinous, low-grade serous, and grade 1 endometrioid ovarian cancer according to NCCN guideline. The recommended course for stage I high-grade serous ovarian cancer patients and stage II-IV EOC patients is 6; for other type of stage I, the recommended course is 3–6. Discussion Surgery is the primary curative treatment for EOC and aims to achieve satisfactory debulking outcomes. However, ovarian carcinomas are usually aggressive and can cause serous abdominal adhesions, increasing surgical difficulty and risk [8]. PRBCT can compensate for blood loss, supply blood volume, and sustain vital organ perfusion, making it an effective treatment for major bleeding and a widely used method in the perioperative period. However, RBC transfusion may promote immunosuppression in a phenomenon known as TRIM. TRIM includes a series of complicated immunological responses that can reduce immune surveillance and cause an immunosuppressive state, thus contributing to the development and recurrence of tumors [12]. The underlying mechanism may be related to the activation of macrophages and monocytes, residual leukocytes, their derived soluble mediators, and soluble HLA antigens in donor plasma [20,21]. However, the effects of PRBCT on cancer development and recurrence remain controversial. Some studies argue that PRBCT could have detrimental effects on tumor growth and dissemination and adversely affect prognosis [22,23]. In contrast, other researchers reached the opposite conclusion, suggesting that PRBCT does not affect OS or PFS in colorectal cancer [24,25]. Several studies have investigated PRBCT and its prognosis in patients with EOC. Beryl et al. evaluated the association of PRBCT with morbidity and oncological outcomes in 270 patients and concluded that PRBCT did not affect PFS or OS [26]. Mette et al. conducted a population-based study of 2654 women with prospectively registered data and found that perioperative blood transfusion adversely affected mortality within one year of primary ovarian cancer surgery [27]. Connor et al. suggested that PRBCT was associated with poor survival in EOC [9], whereas Hunsicker et al. suggested that PRBCT did not increase the risk of recurrence [28]. By examining 121 (38.54 %) patients who underwent PRBCT, we found that PRBCT was associated with higher preoperative serum CA-125 levels, higher intraoperative blood loss, larger ascites volume, lower hemoglobin levels at diagnosis, longer operative time, lower lymph node dissection rate, a lower likelihood of satisfactory debulking surgery, higher relapse rates, and higher mortality rates. The Cox multivariate proportional hazard regression analysis revealed that PRBCT was an independent prognostic factor for EOC. Transfused patients were 1.59 times more at risk of death than non-transfused patients (HR = 1.59; 95%CI, 1.12–2.25) and 1.63 times more at risk of recurrence than non-transfused patients (HR = 1.63; 95%CI, 1.22–2.18). Considering the potential adverse effects of PRBCT, administering proper transfusions to the correct patient is crucial. In 2016, the American Association of Blood Banks (AABB) released the transfusion guidelines [19] regarding the target hemoglobin level for RBC transfusion among hospitalized adult patients who were hemodynamically stable. The AABB states that a restrictive RBC transfusion threshold, in which transfusion is not indicated until a hemoglobin level of 7 g/dL is recommended for hospitalized adult patients who are hemodynamically stable, including critically ill patients, rather than when the hemoglobin level is 10 g/dL. A restrictive RBC transfusion threshold of 8 g/dL is recommended for patients undergoing orthopedic surgery, cardiac surgery, or those with preexisting cardiovascular diseases. In our study, only 13 (10.74 %) patients who underwent PRBCT met these criteria, indicating the need to enhance perioperative blood management. The presence of anemia should be investigated in all surgical procedures, with an expected moderate-to-high blood loss (>500 ml) [29]. Oral iron, intravenous iron, and/or recombinant erythropoietin can treat preoperative anemia. In addition, a reduction in blood loss and bleeding is critical. An individualized assessment of bleeding risk, including family history, hematological disorders, and the use of anticoagulants and antiplatelet medications, should be performed before surgery. If significant blood loss is anticipated, pharmacological treatments such as tranexamic acid and fibrin sealants should be administered promptly [30]. Notably, rather than being caused by PRBCT, a poor prognosis in patients undergoing PRBCT could also be caused by clinical conditions that require PRBCT, such as advanced tumor stage, difficulty and duration of surgery, and comorbidities. In other words, an uncontrolled confounding bias could have caused a significant association between PRBCT and a poor prognosis; PRBCT itself may not lead to decreased survival but is just a surrogate marker for patients with a poor prognosis. Unfortunately, it was difficult to effectively control for confounding biases. Many studies have used various statistical methods to reduce bias [14,31,32]. However, significant knowledge gaps remain regarding the relationship between PRBCT and EOC prognosis. Our study has the following limitations. The proportions of patients with high CA125 levels, large ascites volume, and preoperative anemia were higher in the PRBCT group than in the non-PRBCT group. Even if we performed a multivariate analysis to determine the factors influencing the prognosis of EOC, we could not completely avoid the possibility of residual confounding due to unmeasured confounders. In addition, considering that our study was a retrospective study from a single center and there were no standard surgery and postoperative care protocols, there could have been increased potential biases and confounding variables. Future multicenter randomized controlled studies following a unified standardized scheme are required to further explore the relationship between PRBCT findings and adverse outcomes in patients with EOC. Despite these limitations, our study provides additional evidence supporting this topic, which remains controversial. Transfusion is critically important in cases of severe intraoperative hemorrhage; however, its excessive use should be avoided. In current clinical practice, some doctors prefer “prophylactic” transfusion to prevent anemia that may occur after surgery. From this point of view, as a result of our study, transfusion decisions should be aided when managing patients with EOC during the perioperative period. However, it is important to confirm these findings through further multicenter randomized controlled studies, given the limitations mentioned above. In conclusion, our study found that PRBCT could prolong hospital stays, increase hospital costs, and be significantly associated with increased cancer recurrence and overall mortality in EOC patients. Although this conclusion needs to be verified by multicenter randomized controlled studies, from the perspective of clinical practice, it is still recommended to use a restricted blood transfusion threshold to guide transfusion, strengthen blood management, and reduce the transfusion rate, which may positively affect the prognosis of patients with EOC. Funding This work was supported by 10.13039/501100001809National Natural Science Foundation of China (82303956). Ethics declarations This study was reviewed and approved by Qilu Hospital of Shandong University Research Ethics Committee, with the approval number: KYLL-2022 (ZM)-484. Data availability statement Data will be made available on request. CRediT authorship contribution statement Yawen Zheng: Writing - original draft, Software, Methodology, Funding acquisition. Wenxia Zhang: Writing - review & editing, Visualization, Software, Methodology. Yafei Chen: Resources, Methodology, Data curation. Xingsheng Yang: Software, Data curation. Ruiying Dong: Writing - review & editing, Conceptualization. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.